Key Insights

Highlights

Treatment Research

4 treatments under study, led by Denosumab

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 1/2 (1)

Trial Status

Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT06374459Phase 1/2RecruitingPrimary

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Showing all 1 trials

Research Network

Common Treatments

  • Denosumab1
  • Zumsemetinib1
  • Capecitabine1
  • Zoledronic Acid1

Active Sponsors

  • Washington University School of Medicine1
  • United States Department of Defense1
  • Aclaris Therapeutics, Inc.1

Top Investigators

Activity Timeline